Keiran S M Smalley

List of Publications by Year
in descending order

185 papers	16,690 citations	23567 58 h-index	15732 125 g-index
192 all docs	192 docs citations	192 times ranked	27518 citing authors

#	Article	IF	Citations
1	Melanoma brain metastases: Biological basis and novel therapeutic strategies. Experimental Dermatology, 2022, 31, 31-42.	2.9	12
2	Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma. Journal of Investigative Dermatology, 2022, 142, 18-20.	0.7	7
3	A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neuro-Oncology, 2022, 24, 1673-1686.	1.2	6
4	HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer Gene Therapy, 2022, 29, 1840-1846.	4.6	3
5	Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clinical Cancer Research, 2022, 28, 2131-2146.	7.0	36
6	Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitorâ€'Resistant Melanoma. Journal of Investigative Dermatology, 2021, 141, 840-851.e4.	0.7	19
7	A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease. Journal of Visualized Experiments, 2021, , .	0.3	4
8	Targeted Therapy Given after Antiâ€"PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunology Research, 2021, 9, 554-567.	3.4	15
9	A Mutational Survey of Acral Nevi. JAMA Dermatology, 2021, 157, 831-835.	4.1	13
10	Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clinical Cancer Research, 2021, 27, 4109-4125.	7.0	65
11	MEK-ing the Most of It: Strategies to Co-target GÎ±q and MAPK in Uveal Melanoma. Clinical Cancer Research, 2021, 27, 1217-1219.	7.0	5
12	Translational pathology, genomics and the development of systemic therapies for acral melanoma. Seminars in Cancer Biology, 2020, 61, 149-157.	9.6	30
13	Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance. Clinical Cancer Research, 2020, 26, 2163-2175.	7.0	39
14	Decitabine limits escape from MEK inhibition in uveal melanoma. Pigment Cell and Melanoma Research, 2020, 33, 507-514.	3.3	17
15	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell and Melanoma Research, 2020, 33, 527-541.	3.3	36
16	Two Worlds Collide: Unraveling the Role of the Immune System in BRAFâ€"MEK Inhibitor Responses. Cancer Discovery, 2020, 10, 176-178.	9.4	11
17	MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer. Cancer Research, 2019, 79, 5812-5825.	0.9	6
18	Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine, 2019, 48, 178-190.	6.1	66

#	Article	IF	Citations
19	HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. Clinical Cancer Research, 2019, 25, 5686-5701.	7.0	75
20	Pharmacological research and cancer: A call to arms. Pharmacological Research, 2019, 146, 104291.	7.1	2
21	K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling. Nature Communications, 2019, 10, 1870.	12.8	61
22	HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. Cancer Research, 2019, 79, 2947-2961.	0.9	59
23	Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?. Melanoma Management, 2019, 6, MMT29.	0.5	3
24	Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology. Survey of Ophthalmology, 2019, 64, 272-288.	4.0	25
25	ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC). Pharmacological Research, 2019, 141, 63-72.	7.1	14
26	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell and Melanoma Research, 2019, 32, 458-469.	3.3	31
27	Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma. Clinical Cancer Research, 2018, 24, 5516-5524.	7.0	55
28	ERK Inhibition: A New Front in the War against MAPK Pathwayâ€“Driven Cancers?. Cancer Discovery, 2018, 8, 140-142.	9.4	40
29	Get with the Program! Stemness and Reprogramming in Melanoma Metastasis. Journal of Investigative Dermatology, 2018, 138, 10-13.	0.7	6
30	The biology and therapeutic management of melanoma brain metastases. Biochemical Pharmacology, 2018, 153, 35-45.	4.4	12
31	Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma. Cancer, 2018, 124, 2254-2255.	4.1	0
32	Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer, 2018, 124, 297-305.	4.1	76
33	Dabrafenib inhibits the growth of BRAFâ€WT cancers through CDK16 and NEK9 inhibition. Molecular Oncology, 2018, 12, 74-88.	4.6	30
34	The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases. Pharmacological Research, 2018, 135, 265-267.	7.1	6
35	Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines. Molecular Cancer Therapeutics, 2018, 17, 73-83.	4.1	18
36	EXTH-39. DETECTION, MOLECULAR PROFILING AND CULTURE OF CSF-CTCs IN LEPTOMENINGEAL DISEASE (LMDz) IN MELANOMA TO IMPROVE DIAGNOSIS AND TREATMENT STRATEGIES. Neuro-Oncology, 2018, 20, vi93-vi93.	1.2	1

#	Article	IF	Citations
37	Frontiers in pigment cell and melanoma research. Pigment Cell and Melanoma Research, 2018, 31, 728-735.	3.3	10
38	Why do women with melanoma do better than men?. ELife, 2018, 7, .	6.0	21
39	Abstract 3025: Ligand-independent EphA2 signaling drives an amoeboid phenotype that promotes melanoma brain metastasis development. Cancer Research, 2018, 78, 3025-3025.	0.9	1
40	Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells. Pharmacological Research, 2017, 119, 242-250.	7.1	32
41	SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer. Bioinformatics, 2017, 33, 2951-2953.	4.1	11
42	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. Clinical Cancer Research, 2017, 23, 6203-6214.	7.0	36
43	Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Research, 2017, 27, 545-557.	1.2	6
44	BRAF-MEK inhibition in melanoma brain metastases: a new hope. Lancet Oncology, The, 2017, 18, 836-837.	10.7	5
45	Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells. Oncogene, 2017, 36, 1849-1861.	5.9	75
46	Experimental Treatments for Leptomeningeal Metastases from Solid Malignancies. Cancer Control, 2017, 24, 42-46.	1.8	11
47	BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma. Melanoma Research, 2016, 26, 83-87.	1.2	21
48	Improving patient outcomes to targeted therapies in melanoma. Expert Review of Anticancer Therapy, 2016, 16, 633-641.	2.4	6
49	Phase i trials in melanoma: A framework to translate preclinical findings to the clinic. European Journal of Cancer, 2016, 67, 213-222.	2.8	32
50	Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. International Journal of Cancer, 2016, 139, 1195-1201.	5.1	41
51	The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416.	3.3	77
52	Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. Journal of Proteome Research, 2016, 15, 4476-4489.	3.7	16
53	Increased immunity and BRAF inhibition: Yet another argument for combination therapy?. Pharmacological Research, 2016, 113, 719-720.	7.1	2
54	A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature. Melanoma Research, 2016, 26, 481-486.	1.2	9

#	Article	IF	Citations
55	The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochemical Pharmacology, 2016, 122, 1-9.	4.4	34
56	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
57	Essential role of HDAC6 in the regulation of PDâ€L1 inÂmelanoma. Molecular Oncology, 2016, 10, 735-750.	4.6	125
58	Combination Therapies for Melanoma: A New Standard of Care?. American Journal of Clinical Dermatology, 2016, 17, 99-105.	6.7	23
59	Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene, 2016, 35, 1225-1235.	5.9	70
60	Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.. Journal of Clinical Oncology, 2016, 34, 9544-9544.	1.6	2
61	Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma. Experimental Dermatology, 2015, 24, 657-658.	2.9	8
62	Phosphoproteomic analysis of basal and therapyâ€induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics, 2015, 15, 327-339.	2.2	13
63	Targeting histone deacetylase 6 mediates a dual antiâ€melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Molecular Oncology, 2015, 9, 1447-1457.	4.6	111
64	Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma. Molecular and Cellular Oncology, 2015, 2, e1008291.	0.7	3
65	Pharmacological research and precision cancer medicine: A call for manuscripts. Pharmacological Research, 2015, 102, 308-309.	7.1	0
66	Introducing a checklist for manuscript submission to Pharmacological Research. Pharmacological Research, 2015, 102, 319-321.	7.1	3
67	Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapyâ€“Mediated Metastatic Melanoma Phenotype. Cancer Discovery, 2015, 5, 264-273.	9.4	82
68	Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods, 2015, 81, 41-49.	3.8	11
69	Inhibition of BRAF and MEK in BRAF-mutant melanoma. Lancet, The, 2015, 386, 410-412.	13.7	8
70	The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. Molecular Cancer Therapeutics, 2015, 14, 1354-1364.	4.1	33
71	BRAF Inhibition Generates a Hostâ€“Tumor Niche that Mediates Therapeutic Escape. Journal of Investigative Dermatology, 2015, 135, 3115-3124.	0.7	80
72	XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation. Journal of Investigative Dermatology, 2015, 135, 2542-2544.	0.7	10

#	Article	IF	Citations
73	Beyond BRAF: where next for melanoma therapy?. British Journal of Cancer, 2015, 112, 217-226.	6.4	99
74	The complexity of microenvironment-mediated drug resistance. Genes and Cancer, 2015, 6, 367-368.	1.9	11
75	Zonula Occludens Protein-1. , 2015, , 4892-4895.		0
76	Zonula Occludens Protein-1. , 2015, , 1-5.		0
77	Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics. Molecular and Cellular Proteomics, 2014, 13, 1844-1854.	3.8	52
78	Inhibition of autophagy enhances the effects of the <scp>AKT</scp> inhibitor <scp>MK</scp>â€2206 when combined with paclitaxel and carboplatin in <scp>BRAF</scp> wildâ€type melanoma. Pigment Cell and Melanoma Research, 2014, 27, 465-478.	3.3	50
79	Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?. Expert Opinion on Pharmacotherapy, 2014, 15, 589-592.	1.8	23
80	Where to start with systemic melanoma therapy?. Melanoma Management, 2014, 1, 15-18.	0.5	0
81	Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Research, 2014, 24, 448-453.	1.2	14
82	Vertical inhibition of the <scp>MAPK</scp> pathway enhances therapeutic responses in <scp>NRAS</scp>â€mutant melanoma. Pigment Cell and Melanoma Research, 2014, 27, 1154-1158.	3.3	47
83	Resistance to Raf inhibition in cancer. Drug Discovery Today: Technologies, 2014, 11, 27-32.	4.0	31
84	Fibroblasts Protect Melanoma Cells from the Cytotoxic Effects of Doxorubicin. Tissue Engineering - Part A, 2014, 20, 2412-2421.	3.1	40
85	Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models. Molecular Cancer Therapeutics, 2014, 13, 2793-2804.	4.1	80
86	Up Close and Personal: The Challenges of Precision Medicine in Melanoma. Journal of the National Cancer Institute, 2014, 106, djt443-djt443.	6.3	4
87	Change or die: Targeting adaptive signaling to kinase inhibition in cancer cells. Biochemical Pharmacology, 2014, 91, 417-425.	4.4	8
88	Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia. Clinical Cancer Research, 2014, 20, 4186-4192.	7.0	61
89	Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.. Journal of Clinical Oncology, 2014, 32, 9062-9062.	1.6	0
90	Fibroblast-mediated drug resistance in cancer. Biochemical Pharmacology, 2013, 85, 1033-1041.	4.4	127

#	Article	IF	Citations
91	Melanoma genotypes and phenotypes get personal. Laboratory Investigation, 2013, 93, 858-867.	3.7	23
92	Mutant BRAF: A Novel Mediator of Microenvironmental Escape in Melanoma?. Journal of Investigative Dermatology, 2013, 133, 1135-1137.	0.7	1
93	In Vivo and in Silico Pharmacokinetics and Biodistribution of a Melanocortin Receptor 1 Targeted Agent in Preclinical Models of Melanoma. Molecular Pharmaceutics, 2013, 10, 3175-3185.	4.6	13
94	Targeted therapy in melanoma. Clinics in Dermatology, 2013, 31, 200-208.	1.6	23
95	Paradoxical oncogenesisâ€"the long-term effects of BRAF inhibition in melanoma. Nature Reviews Clinical Oncology, 2013, 10, 390-399.	27.6	171
96	Senescent Fibroblasts in Melanoma Initiation and Progression: An Integrated Theoretical, Experimental, and Clinical Approach. Cancer Research, 2013, 73, 6874-6885.	0.9	51
97	Targeted therapy for melanoma: is double hitting a home run?. Nature Reviews Clinical Oncology, 2013, 10, 5-6.	27.6	12
98	NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene, 2013, 32, 3009-3018.	5.9	127
99	Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma. Molecular Cancer Therapeutics, 2013, 12, 901-912.	4.1	52
100	Taming the Wild-Types: Targeting PAK1 in Melanomas That Lack BRAF Mutations. Journal of the National Cancer Institute, 2013, 105, 591-592.	6.3	4
101	Conjunctival Melanomas Harbor BRAF and NRAS Mutationsâ€"Letter. Clinical Cancer Research, 2013, 19, 6329-6330.	7.0	28
102	Vemurafenib Potently Induces Endoplasmic Reticulum Stressâ€"Mediated Apoptosis in BRAFV600E Melanoma Cells. Science Signaling, 2013, 6, ra7.	3.6	114
103	An Unholy Alliance: Cooperation between BRAF and NF1 in Melanoma Development and BRAF Inhibitor Resistance. Cancer Discovery, 2013, 3, 260-263.	9.4	37
104	Overcoming melanoma drug resistance through metabolic targeting?. Pigment Cell and Melanoma Research, 2013, 26, 793-795.	3.3	0
105	Novel Treatments for Melanoma Brain Metastases. Cancer Control, 2013, 20, 298-306.	1.8	14
106	The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling. PLoS ONE, 2013, 8, e59588.	2.5	58
107	The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms. Clinical Cancer Research, 2012, 18, 2502-2514.	7.0	145
108	A brief history of melanoma. Melanoma Research, 2012, 22, 114-122.	1.2	111

#	Article	IF	Citations
109	Targeting Mutant BRAF in Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 124-131.	2.0	70
110	Making Sense of MEK1 Mutations in Intrinsic and Acquired BRAF Inhibitor Resistance: Figure 1.. Cancer Discovery, 2012, 2, 390-392.	9.4	10
111	Preface. Advances in Pharmacology, 2012, 65, xi-xiii.	2.0	0
112	GSK3Î² Inhibition Blocks Melanoma Cell/Host Interactions by Downregulating N-Cadherin Expression and Decreasing FAK Phosphorylation. Journal of Investigative Dermatology, 2012, 132, 2818-2827.	0.7	37
113	The Current State of Targeted Therapy in Melanoma: This Time It's Personal. Seminars in Oncology, 2012, 39, 204-214.	2.2	27
114	Melanoma and Other Skin Cancers. , 2012, , 439-468.		0
115	Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma. Expert Opinion on Investigational Drugs, 2011, 20, 137-140.	4.1	10
116	Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance. Molecular Pharmaceutics, 2011, 8, 2039-2049.	4.6	109
117	Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochemical Pharmacology, 2011, 82, 201-209.	4.4	162
118	Ipilimumab. Nature Reviews Drug Discovery, 2011, 10, 411-412.	46.4	135
119	A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics - Clinical Applications, 2011, 5, 383-396.	1.6	48
120	PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression. Cancer Research, 2011, 71, 2750-2760.	0.9	488
121	Identification ofBRAFmutations in eruptive melanocytic nevi: new insights into melanomagenesis?. Expert Review of Anticancer Therapy, 2011, 11, 711-714.	2.4	17
122	Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget, 2011, 2, 329-335.	1.8	19
123	Zonula Occludens Protein-1. , 2011, , 3981-3984.		0
124	Introduction to the Biochemical Pharmacology special issue on targeted cancer therapy. Biochemical Pharmacology, 2010, 80, 549.	4.4	0
125	Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. Biochemical Pharmacology, 2010, 80, 739-747.	4.4	15
126	Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. British Journal of Cancer, 2010, 102, 1724-1730.	6.4	283

#	Article	IF	Citations
127	Melanoma â€" An Unlikely Poster Child for Personalized Cancer Therapy. New England Journal of Medicine, 2010, 363, 876-878.	27.0	70
128	Measurement of Constitutive MAPK and PI3K/AKT Signaling Activity in Human Cancer Cell Lines. Methods in Enzymology, 2010, 484, 549-567.	1.0	14
129	Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy. Journal of Investigative Dermatology, 2010, 130, 28-37.	0.7	116
130	PLX4032, a potent inhibitor of the Bâ€Raf V600E oncogene, selectively inhibits V600Eâ€positive melanomas. Pigment Cell and Melanoma Research, 2010, 23, 820-827.	3.3	142
131	PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Current Opinion in Investigational Drugs, 2010, 11, 699-706.	2.3	40
132	The future of targeted therapy approaches in melanoma. Expert Opinion on Drug Discovery, 2009, 4, 445-456.	5.0	1
133	Genetic Subgrouping of Melanoma Reveals New Opportunities for Targeted Therapy: Figure 1.. Cancer Research, 2009, 69, 3241-3244.	0.9	78
134	Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncology, 2009, 5, 775-778.	2.4	18
135	Integrating tumorâ€initiating cells into the paradigm for melanoma targeted therapy. International Journal of Cancer, 2009, 124, 1245-1250.	5.1	15
136	CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene, 2009, 28, 85-94.	5.9	195
137	Integrating BRAF/MEK inhibitors into combination therapy for melanoma. British Journal of Cancer, 2009, 100, 431-435.	6.4	82
138	Melanoma Biomarkers. Molecular Diagnosis and Therapy, 2009, 13, 283-296.	3.8	36
139	Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report. Pigment Cell and Melanoma Research, 2009, 22, 386-387.	3.3	10
140	Preclinical and clinical development of targeted therapy in melanoma: attention to schedule. Pigment Cell and Melanoma Research, 2009, 22, 529-531.	3.3	11
141	c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histology and Histopathology, 2009, 24, 643-50.	0.7	64
142	Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. Molecular Diagnosis and Therapy, 2009, 13, 283-96.	3.8	16
143	Similar Biological Activities of Two Isostructural Ruthenium and Osmium Complexes. Chemistry - A European Journal, 2008, 14, 4816-4822.	3.3	85
144	The Essential Role of Fibroblasts in Esophageal Squamous Cell Carcinomaâ€"Induced Angiogenesis. Gastroenterology, 2008, 134, 1981-1993.	1.3	118

#	Article	IF	Citations
145	Somatic genetics and targeted therapies for cutaneous melanoma. Update on Cancer Therapeutics, 2008, 3, 81-87.	0.4	0
146	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3041-3046.	7.1	1,206
147	Structure-Based Design of an Organoruthenium Phosphatidyl-inositol-3-kinase Inhibitor Reveals a Switch Governing Lipid Kinase Potency and Selectivity. ACS Chemical Biology, 2008, 3, 305-316.	3.4	51
148	In vitrothree-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opinion on Drug Discovery, 2008, 3, 1-10.	5.0	105
149	Cytotoxicity of the matrix metalloproteinaseâ€“activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Molecular Cancer Therapeutics, 2008, 7, 1218-1226.	4.1	18
150	The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel. Clinical Cancer Research, 2008, 14, 230-239.	7.0	214
151	Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600Eâ€“mutated melanomas. Molecular Cancer Therapeutics, 2008, 7, 2876-2883.	4.1	284
152	Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression. Cancer Research, 2008, 68, 5743-5752.	0.9	90
153	Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Molecular Cancer Therapeutics, 2008, 7, 2866-2875.	4.1	66
154	Therapeutic Targeting of the Melanoma Stem Cell Population. Translational Medicine Series, 2008, , 83-98.	0.0	0
155	Targeting BRAF Activity as a NovelParadigm for Melanoma Therapy. Translational Medicine Series, 2008, , 67-82.	0.0	0
156	Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. British Journal of Cancer, 2007, 96, 445-449.	6.4	89
157	Targeting BRAF/MEK in melanoma: new hope or another false dawn?. Expert Review of Dermatology, 2007, 2, 179-190.	0.3	0
158	Is ERK activation a good biomarker for estradiol and tamoxifen effects?. Cancer Biology and Therapy, 2007, 6, 119-120.	3.4	1
159	An Organometallic Protein Kinase Inhibitor Pharmacologically Activates p53 and Induces Apoptosis in Human Melanoma Cells. Cancer Research, 2007, 67, 209-217.	0.9	224
160	Dysregulation of Claudin-7 Leads to Loss of E-Cadherin Expression and the Increased Invasion of Esophageal Squamous Cell Carcinoma Cells. American Journal of Pathology, 2007, 170, 709-721.	3.8	123
161	Rewired ERK-JNK Signaling Pathways in Melanoma. Cancer Cell, 2007, 11, 447-460.	16.8	260
162	Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885. Cancer Research, 2006, 66, 11100-11105.	0.9	257

#	Article	IF	Citations
163	LIFE ISN'T FLAT: TAKING CANCER BIOLOGY TO THE NEXT DIMENSION. In Vitro Cellular and Developmental Biology - Animal, 2006, 42, 242.	1.5	258
164	Defining the Conditions for the Generation of Melanocytes from Human Embryonic Stem Cells. Stem Cells, 2006, 24, 1668-1677.	3.2	113
165	Towards the Targeted Therapy of Melanoma. Mini-Reviews in Medicinal Chemistry, 2006, 6, 387-393.	2.4	23
166	Notch1 Signaling Promotes Primary Melanoma Progression by Activating Mitogen-Activated Protein Kinase/Phosphatidylinositol 3-Kinase-Akt Pathways and Up-regulating N-Cadherin Expression. Cancer Research, 2006, 66, 4182-4190.	0.9	251
167	Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Molecular Cancer Therapeutics, 2006, 5, 1136-1144.	4.1	410
168	Targeting Intracellular Signaling Pathways as a Novel Strategy in Melanoma Therapeutics. Annals of the New York Academy of Sciences, 2005, 1059, 16-25.	3.8	78
169	Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell & Melanoma Research, 2005, 18, 150-159.	3.6	304
170	Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Seminars in Cancer Biology, 2005, 15, 451-459.	9.6	53
171	Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Expert Review of Anticancer Therapy, 2005, 5, 1069-1078.	2.4	20
172	Up-Regulated Expression of Zonula Occludens Protein-1 in Human Melanoma Associates with N-Cadherin and Contributes to Invasion and Adhesion. American Journal of Pathology, 2005, 166, 1541-1554.	3.8	143
173	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Frontiers in Bioscience - Landmark, 2005, 10, 2986.	3.0	227
174	Loitering with Intent: New Evidence for the Role of BRAF Mutations in the Proliferation of Melanocytic Lesions. Journal of Investigative Dermatology, 2004, 123, xvi-xvii.	0.7	12
175	The Role of Altered Cellâ€“Cell Communication in Melanoma Progression. Journal of Molecular Histology, 2003, 35, 309-318.	2.2	135
176	A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. International Journal of Cancer, 2003, 104, 527-532.	5.1	312
177	Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. International Journal of Cancer, 2003, 105, 165-175.	5.1	97
178	The Great Escape: Another Way for Melanoma to Leave Physiological Control?. Journal of Investigative Dermatology, 2003, 121, xi-xii.	0.7	0
179	Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest. Melanoma Research, 2002, 12, 187-192.	1.2	31
180	Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. International Journal of Cancer, 2002, 98, 514-522.	5.1	46

#	Article	IF	Citations
181	The treatment of advanced renal cell cancer with high-dose oral thalidomide. British Journal of Cancer, 2001, 85, 953-958.	6.4	102
182	Ligand internalization and recycling by human recombinant somatostatin type 4 (h sst4) receptors expressed in CHO-K1 cells. British Journal of Pharmacology, 2001, 132, 1102-1110.	5.4	20
183	The involvement of p38 mitogen-activated protein kinase in the Î±-melanocyte stimulating hormone (Î±-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. FEBS Letters, 2000, 476, 198-202.	2.8	140
184	The Pivotal Role of Phosphoinositide-3 Kinase in the Human Somatostatin sst4 Receptor-Mediated Stimulation of p44/p42 Mitogen-Activated Protein Kinase and Extracellular Acidification. Biochemical and Biophysical Research Communications, 1999, 263, 239-243.	2.1	32
185	Differential agonist activity of somatostatin and L-362855 at human recombinant sst4 receptors. British Journal of Pharmacology, 1998, 125, 833-841.	5.4	25